UBS Group’s AbbVie ABBV Stock Holding History

UBS Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.06B	Buy	14,051,196 +3,524,276	+33%	+$782M	0.46%	21
2025 Q4	$2.41B	Sell	10,526,920 -1,191,316	-10%	-$271M	0.39%	25
2025 Q3	$2.71B	Sell	11,718,236 -86,248	-0.7%	-$17.6M	0.43%	24
2025 Q2	$2.19B	Buy	11,804,484 +91,644	+0.8%	+$17M	0.38%	33
2025 Q1	$2.45B	Sell	11,712,840 -867,368	-7%	-$169M	0.45%	21
2024 Q4	$2.24B	Buy	12,580,208 +1,086,102	+9%	+$200M	0.41%	27
2024 Q3	$2.27B	Sell	11,494,106 -383,411	-3%	-$71.6M	0.49%	24
2024 Q2	$2.04B	Buy	11,877,517 +1,369,308	+13%	+$227M	0.5%	25
2024 Q1	$1.91B	Sell	10,508,209 -396,913	-4%	-$68.4M	0.48%	25
2023 Q4	$1.69B	Buy	10,905,122 +345,137	+3%	+$50.3M	0.51%	26
2023 Q3	$1.57B	Sell	10,559,985 -551,084	-5%	-$80.9M	0.54%	23
2023 Q2	$1.5B	Buy	11,111,069 +213,830	+2%	+$31.4M	0.51%	30
2023 Q1	$1.74B	Buy	10,897,239 +88,432	+0.8%	+$13.5M	0.63%	15
2022 Q4	$1.75B	Buy	10,808,807 +939,799	+10%	+$144M	0.65%	14
2022 Q3	$1.32B	Buy	9,869,008 +116,678	+1%	+$16.7M	0.58%	18
2022 Q2	$1.49B	Buy	9,752,330 +604,659	+7%	+$92.4M	0.61%	18
2022 Q1	$1.48B	Sell	9,147,671 -573,850	-6%	-$83.4M	0.49%	29
2021 Q4	$1.32B	Buy	9,721,521 +62,634	+0.6%	+$7.4M	0.38%	42
2021 Q3	$1.04B	Buy	9,658,887 +21,075	+0.2%	+$2.41M	0.33%	55
2021 Q2	$1.09B	Buy	9,637,812 +398,307	+4%	+$44.9M	0.35%	49
2021 Q1	$1,000M	Sell	9,239,505 -316,343	-3%	-$33.8M	0.33%	55
2020 Q4	$1.02B	Buy	9,555,848 +883,025	+10%	+$84.9M	0.35%	55
2020 Q3	$760M	Buy	8,672,823 +868,655	+11%	+$81.8M	0.29%	76
2020 Q2	$766M	Buy	7,804,168 +1,478,977	+23%	+$130M	0.32%	64
2020 Q1	$482M	Buy	6,325,191 +764,906	+14%	+$65.2M	0.23%	99
2019 Q4	$492M	Buy	5,560,285 +405,020	+8%	+$33.6M	0.17%	138
2019 Q3	$390M	Sell	5,155,265 -839,964	-14%	-$57.6M	0.15%	149
2019 Q2	$436M	Sell	5,995,229 -212,821	-3%	-$16.7M	0.17%	137
2019 Q1	$500M	Buy	6,208,050 +420,356	+7%	+$34.4M	0.21%	117
2018 Q4	$534M	Sell	5,787,694 -848,068	-13%	-$74.6M	0.24%	95
2018 Q3	$628M	Sell	6,635,762 -609,090	-8%	-$57.8M	0.25%	84
2018 Q2	$671M	Buy	7,244,852 +527,218	+8%	+$51.5M	0.29%	67
2018 Q1	$636M	Sell	6,717,634 -1,183,562	-15%	-$130M	0.27%	77
2017 Q4	$764M	Sell	7,901,196 -74,161	-0.9%	-$6.99M	0.31%	69
2017 Q3	$709M	Sell	7,975,357 -446,930	-5%	-$34M	0.33%	60
2017 Q2	$611M	Buy	8,422,287 +518,997	+7%	+$34.9M	0.32%	65
2017 Q1	$515M	Sell	7,903,290 -45,660	-0.6%	-$2.87M	0.28%	72
2016 Q4	$498M	Sell	7,948,950 -26,153	-0.3%	-$1.6M	0.27%	71
2016 Q3	$503M	Buy	7,975,103 +104,712	+1%	+$6.78M	0.3%	65
2016 Q2	$487M	Buy	7,870,391 +130,397	+2%	+$7.95M	0.31%	59
2016 Q1	$442M	Buy	7,739,994 +537,572	+7%	+$30M	0.3%	60
2015 Q4	$427M	Buy	7,202,422 +78,170	+1%	+$4.5M	0.28%	67
2015 Q3	$388M	Buy	7,124,252 +165,968	+2%	+$10.8M	0.27%	65
2015 Q2	$468M	Buy	6,958,284 +363,392	+6%	+$23.7M	0.31%	54
2015 Q1	$386M	Buy	6,594,892 +1,625,064	+33%	+$98.2M	0.27%	74
2014 Q4	$325M	Buy	+4,969,828	New	+$313M	0.23%	90

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group's ABBV Position: Q1 2026 in Review

UBS Group increased its AbbVie (ABBV) stake by 33% in Q1 2026, buying an estimated $782M and bringing the position to 14,051,196 shares worth $3.06B. The position accounts for 0.46% of the portfolio, ranked #21.

UBS Group first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

UBS Group held 14,051,196 shares of AbbVie worth $3.06B as of Q1 2026.
UBS Group bought 3,524,276 AbbVie shares in Q1 2026, an estimated $782M.
AbbVie made up 0.46% of UBS Group's portfolio in Q1 2026, its #21 holding.
UBS Group first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.